Medicine and Dentistry
Head and Neck Cancer
97%
Neck
90%
Oropharynx Squamous Cell Carcinoma
77%
Robot-Assisted Surgery
72%
Wart Virus
65%
Neoplasm
64%
Radiation Therapy
58%
Oral Cancer
55%
Overall Survival
50%
Diagnosis
45%
Neck Dissection
42%
Squamous Cell Carcinoma
42%
Mouth Squamous Cell Carcinoma
41%
Sentinel Node
39%
Prognostic Factor
38%
Malignant Neoplasm
36%
Surgery
36%
Recurrent Disease
35%
Oropharyngeal Cancer
34%
Biopsy
33%
Primary Tumor
33%
Tracheotomy
31%
Metastatic Carcinoma
31%
Cancer of Unknown Primary Origin
29%
Salivary Gland Carcinoma
28%
Disease
28%
Pediatrics
27%
Survival Rate
27%
Oral Cavity
27%
Recurrence Free Survival
26%
Quality of Life
23%
Disease Specific Survival
22%
Lymph Node
20%
Surgeon
19%
Lymph Node Metastasis
18%
Cylindroma
18%
Chemoradiotherapy
17%
Cancer
16%
Receptor
16%
Epidermal Growth Factor Receptor
15%
Cannula
15%
Microvascular Reconstruction
15%
Salivary Gland Cancer
15%
Laryngectomy
15%
Urokinase Receptor
15%
Cohort Analysis
15%
Pediatric Cancer
15%
Thromboplastin
15%
Phase II Trials
15%
Fine-Needle Aspiration
15%
Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
100%
Head-and-neck Cancer
90%
Denmark
82%
Transoral Robotic Surgery
72%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
55%
Neck Dissection
44%
Head-and-neck
44%
High-risk Human Papillomavirus (HR-HPV)
43%
Oral Cancer
41%
Radiotherapy
38%
Overall Survival
31%
Prognostic Factors
29%
Salivary Duct Carcinoma
28%
Sentinel Lymph Node Biopsy
27%
Tumor
25%
Recurrence-free Survival
24%
5-year Survival
22%
Disease-specific Survival
22%
Primary Tumor
21%
Sentinel Lymph Node
21%
Near-infrared Fluorescence Imaging
20%
Cancer Center
20%
Histology
20%
Age-specific Incidence
19%
Occult Metastasis
19%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
19%
Incidence Rate
18%
Older Adults
18%
Pediatric
18%
Adenoid Cystic Carcinoma
18%
Survival Rate
17%
Children with Cancer
16%
Salivary Gland Cancer
15%
Plasminogen Receptor
15%
Expression Pattern
15%
Validation Studies
15%
Microvascular Reconstruction
15%
Chemoradiation
15%
Oral Cavity Cancer
15%
Transtracheal Cannula
15%
Fine-needle Aspiration
15%
Retrospective Longitudinal Study
15%
Phase II Trial
15%
Lymph Node Ratio
15%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
15%
Cricothyroidotomy
15%
Tissue Factor
15%
Enhanced Recovery after Surgery (ERAS®)
15%
Diagnostic Accuracy
14%
Postoperative Complications
14%